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Highly active antiretroviral therapy (HAART) may be a con-
tributory factor for a decreased bone mass and altered bone
metabolism in HIV-infected children. However, the evolution
of bone mineral density (BMD) and bone metabolism during
HAART has not been studied yet. In the current longitudinal
study we monitored the changes of BMD and bone metabolism
over a period of 12 months. Thirty-two HIV-infected children
(15 girls and 17 boys), aged from 6.3 to 17.7 yr, with a long
duration of HAART exposure (40.0 months at baseline) were
enrolled in the study. As a control group, 381 healthy volun-
teers of comparable age were assessed. BMD was measured at
the lumbar spine and whole skeleton by dual-energy x-ray
absorptiometry. Bone-specific alkaline phosphatase (BALP,
as bone formation index) and N-terminal telopeptide of type
I collagen (as bone resorption index) were measured in serum
and urine, respectively. BMD values at baseline were signif-
icantly lower at all skeletal sites than those of control subjects.
The annual increment of spine BMD was comparable to nor-
mal, whereas that of the whole skeleton was significantly
lower (P < 0.04). BALP and N-terminal telopeptide of type I
collagen concentrations were significantly higher compared
with controls at baseline and at follow-up. BALP annual
changes of HIV patients were significantly different from nor-
mal. Our data confirm the presence of low BMD and bone
metabolism derangement in HIV-infected children treated
with HAART. The role of possible therapeutic approach to
restore bone mass and metabolism should be assessed in
pediatrics. (J Clin Endocrinol Metab 89: 24–28, 2004)
THE USE OF highly active antiretroviral therapy(HAART) has consistently decreased morbidity and
mortality rates of HIV-infected patients (1). However,
HAART has been associated with the development of several
acute and chronic complications (2–4). Osteopenia, osteopo-
rosis, and impairments of bone metabolism have been re-
cently reported as frequent findings in HAART-treated pa-
tients (5–9). To date, no definitive cause for bone mass and
bone metabolism alterations has been found. Variable asso-
ciations with the use of protease inhibitors (PIs), develop-
ment of lipodystrophy, nutritional and hormonal factors,
and HIV infection per se have been proposed (5, 10, 11).
Reduced bone mineral density (BMD) has also been found
in HIV-infected children receiving antiretroviral treatment
(12–15). This observation is of great concern because of the
dramatic improvement in life expectancy of HIV-infected
children. Childhood and adolescence are in fact crucial pe-
riods of life for the attainment of an optimal bone mass. Bone
mass changes markedly during childhood and adolescence,
to reach a peak in the third decade of life (16, 17), and peak
bone mass is a major determinant for the development of
osteoporosis later in life. Therefore, impairments in obtaining
an optimal bone mass should be identified during childhood
to avoid future complications.
Bone metabolism rate can be precisely assessed by histo-
morphometry of the iliac crest, which represents the gold
standard for estimating the status of bone turnover (18).
However, bone biopsy is an invasive procedure that is not
feasible for routine use in the evaluation of bone metabolism.
More readily available to physicians and researchers are
biochemical tests performed on blood or urine samples,
which mirror the ongoing bone metabolic processes (19).
These biochemical markers are based on the measurements
of either an enzymatic activity characteristic of the bone-
forming or -resorbing cells or bone matrix components re-
leased into the circulation during bone apposition or resorp-
tion. The concentration of bone metabolism markers changes
markedly during childhood and adolescence. Maximum lev-
els are observed in infancy and during the pubertal period
when skeletal growth is more rapid (20–22). HAART-treated
children and adolescents show remarkable alterations of
bone metabolism rate, assessed by biochemical markers of
bone turnover (12–14).
The evolution of bone mineralization and metabolism over
time in HAART-treated patients has been scarcely studied.
Few studies reporting conflicting results were performed in
adults (23–25), but no data are available for HIV-infected
youths. The lack of knowledge about the changes that occur
over time prompted us to study longitudinally a group of
vertically HIV-infected children and adolescents treated with
HAART, and to compare the measurements with those ob-
tained in a large control population.
Abbreviations: BALP, Bone-specific alkaline phosphatase; BCE, bone
collagen equivalents; BMD, bone mineral density; CV, coefficient of
variation; HAART, highly active antiretroviral therapy; PI, protease
inhibitor; sBMD, spinal BMD.
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Subjects and Methods
Subjects
Eligible for the present study were HIV-infected Caucasian children
and adolescents who were receiving a protease inhibitor (PI)-based
HAART regimen and who were followed at the Pediatric Unit of L. Sacco
Hospital in Milan. Forty patients agreed to participate in the study, but
only 37 completed the 1-yr follow-up. One patient was excluded because
of African descent and four because they did not receive antiviral treat-
ment. We therefore studied 32 patients (15 girls and 17 boys), aged from
6.3 to 17.7 yr at baseline (Table 1). None of the subjects had clinically
apparent renal, cardiac, or intercurrent disease at the time of evaluation.
None of the children had previously received or were currently treated
with sex hormones, corticosteroids, vitamin D, or calcium preparations.
All 32 HIV patients were receiving antiretroviral treatment with d4T,
3TC, and one PI (25 patients received indinavir, five received ritonavir,
and two received nelfinavir). All patients had a long-lasting immune
recovery and control of viral replication (Table 1).
As a control group, we studied 381 healthy volunteers (172 girls and
209 boys) of comparable age (5.7 to 19.2 yr). All subjects were healthy
and appropriately physically active for their age; none was involved in
competitive sport activities. Their mean height and weight measure-
ments were 146.9 (0.9) cm and 42.0 (0.8) kg, respectively. Candidates
were excluded if their anthropometric measurements were not within
the 3rd and 97th centiles for age (26), if they had a history of chronic
illness, if they had one or more fractures, and if they had taken any
medication, hormone, vitamin preparation, or calcium supplements
regularly.
All candidates for this study underwent physical examination to
obtain anthropometric measures and to assess pubertal development.
Body weight was measured to the nearest 0.1 kg on a balance beam scale
(Seca, Hamburg, Germany), and height was measured to the nearest
millimeter using a wall-mounted stadiometer (Holtain Ltd., Crosswell,
UK). Pubertal stage was defined according to Tanner criteria (27). None
of the children had delayed puberty. The ages of the HIV-infected girls
at Tanner stages II, III, IV, and V (10.3, 11.9, 14.0, and 15.9 yr, respec-
tively) were similar to those of the healthy girls (10.7, 12.3, 14.3, and 16.7
yr). Similarly, the ages of HIV-infected boys at Tanner stages II, III, IV,
and V (11.7, 13.2, 14.6, and 16.8 yr, respectively) did not differ from those
of control boys (12.4, 13.7, 15.1, 17.6 yr).
Informed consent was obtained from all the parents or legal guard-
ians of all patients and volunteers. The study was made in accordance
to the Declaration of Helsinki, and the Ethical Committee of L. Sacco
Hospital approved it.
Study protocol
Bone mineral measurements and assessment of biochemical markers
of bone turnover were obtained at baseline and after about 1 yr [12.5 (0.1)
months]. Control subjects were studied only once for ethical reasons.
Bone mineral measurements
BMD was measured at the L2–L4 vertebrae level and in the whole
skeleton. Longitudinal data indicate a differential growth pattern of
arms and legs in HAART-treated children (28). Therefore, BMD values
of arms and legs were obtained from the whole body scan. The data were
analyzed with proper pediatric software (version 1.5h, Lunar Corp.,
Madison, WI). BMD measurements were made with a dual-energy x-ray
absorptiometer (DPX-L, Lunar Radiation Corp., Madison, WI). The in-
strument was calibrated on a daily basis according to the manufacturer’s
instructions. Reproducibility was calculated as coefficient of variation
(CV) obtained by weekly measurements of a standard phantom on the
instrument and by repeated measurements obtained in three children of
different ages. The CV of our instrument is 0.6% with the standard
phantom; in vivo we calculated a CV of 1.4% for the lumbar spine and
1.5% for the whole skeleton. According to published data, the effective
radiation dose for each scan is about 0.3 Sv for the lumbar spine and
less than 0.03 Sv for the whole body scans (29).
Biochemical measurements
Blood was allowed to clot immediately after venipuncture; serum was
separated by centrifugation, and it was stored at 30 C until analysis.
Urine specimens were collected between 1000 and 1200 h as the second
voiding of the day, to minimize the effect of circadian rhythm of ex-
cretion of collagen degradation products (21). Samples were aliquoted
immediately and stored at 30 C until analysis.
Bone-specific alkaline phosphatase (BALP) was measured in serum
as a bone formation marker, using a commercial immunoassay (Metra
BAP, Quidel Corp., San Diego, CA). Intraassay reproducibility was less
than 4%, and interassay variation was less than 7%. Sensitivity was 0.7
U/liter.
We measured urine concentration of N-terminal telopeptide of type
I collagen (NTx) as a bone resorption index. NTx was measured using
an enzyme-immunosorbent assay (Osteomark, Ostex, Seattle, WA). As-
say values were standardized to an equivalent amount of bone collagen
and were expressed in nanomoles bone collagen equivalents (BCE) per
liter (nmol BCE/liter). The sample results from a single urine collection
were normalized for urine dilution by urine creatinine analysis and were
reported as nanomoles BCE/millimoles creatinine. In our laboratory, the
intraassay variation was less than 10%. The interassay precision was less
than 9%, and sensitivity was 20 nmol BCE/liter.
Urine creatinine was measured by a standard automated method.
The determination of HIV-1 copy numbers was carried out using a
quantitative chain reaction assay (Amplicor HIV Monitor, Roche Diag-
nostic Systems, Basel, Switzerland) according to the manufacturer’s
instructions.
Statistical analysis
Descriptive statistics were calculated for all the variables, and data are
expressed as the mean (se), unless otherwise stated. All statistical anal-
yses were conducted at the   0.05 level and were two-tailed. Distri-
bution of the variables were checked using the Shapiro-Wilk W test. The
statistical software JMP IN (SAS Institute, Inc., Cary, NC) was used for
the analyses.
Multivariate analyses were performed to evaluate the differences
between HIV patients and control subjects, after controlling for con-
founding variables. Bone metabolism indices or bone mineral measure-
ments were the dependent variables, whereas sex, age, Tanner stage, and
anthropometric measurements were the confounding variables, and
presence of HIV disease was the independent dichotomous variable.
TABLE 1. Characteristics of 32 vertically HIV-infected children
at baseline and after 12 months of additional exposure to HAART
Baseline After12 months
Age (yr) 12.4 (0.5) 13.4 (0.5)
Weight (kg) 40.8 (2.4) 44.8 (2.3)
(Z-score) 0.77 (0.19) 0.71 (0.18)
Height (cm) 146.9 (2.9) 153.1 (15.8)
(Z-score) 0.65 (0.22) 0.48 (0.17)
Pubertal development
(Tanner stage) I  8 I  5
II  10 II  3
III  4 III  5
IV  1 IV  4
V  9 V  15
CDC clinical stage A  11
B  9
C  12
CDC immunological stage 1  7
2  14
3  11
Previous zidovudine/zidovudine 
didanosine exposure (months)
41.0 (5.1)
Stavudine  lamuvidine  PI
exposure (months)
40.0 (0.7) 52.3 (0.7)
CD4 cells ( 106 cells/liter) 986.0 (81.2) 965.3 (63.3)
CD4 cells (%) 31.6 (1.8) 34.0 (1.5)
Children with HIV-RNA  50
copies/ml
32 32
Data are expressed as mean (SE).
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When analyzing BMD variables, bone area was included in the multi-
variate model. All anthropometric measurements were initially in-
cluded, and the backward procedure was used to build the best model.
Changes of BMD and bone metabolism indices that occurred during
the year of follow-up have been compared with those estimated for
healthy children and calculated in the control group as previously de-
scribed (30). Briefly, slopes for age changes were obtained using regres-
sion analyses, with age as the independent variable and BMD or bone
metabolism markers as the dependent variable. Estimated values were
then calculated for baseline and follow-up measurements. The differ-
ence between the two estimates was then compared with that observed
during follow-up using paired t test. The equations used to obtain
estimated values of BMD were:
sBMD 0.720 0.030 age 0.00326 age2
TBBMD 0.943 0.026 age 0.00234 age2
Arms BMD 0.547 0.00583 age 0.00145 age2
Legs BMD 0.706 0.00094 age 0.00207 age2
The equations used to obtain estimated values of bone metabolism
markers were:
BALP 343.01 127.75 age 10.4 age2 0.248 age3
NTx725.34 264.26 age 20.98 age2 0.48 age3
Patients were grouped according to the clinical and immunological
stage of disease. Comparisons between the groups have been conducted
using multivariate analyses to correct for sex, age, and anthropometric
differences.
Results
Bone mineral measurements
The values of bone mineral measurements of HIV patients
are shown in Table 2. Lumbar spine and whole skeleton BMD
values of control subjects were 0.869 (0.018) and 0.996 (0.012)
g/cm2, respectively, whereas BMD values of arms and legs
were 0.707 (0.011) and 1.021 (0.019) g/cm2, respectively.
Multivariate models for the comparison between the two
groups included sex, age, Tanner stage, and weight as the
confounding variables. Spine BMD measurements of HIV
patients were significantly lower compared with control sub-
jects at baseline ( 0.049; P 0.0001) and at follow-up (
0.055; P  0.0001). Similarly, BMD values of the whole skel-
eton were lower in HIV patients at baseline (  0.045; P 
0.0001) and after 1 yr ( 0.061; P 0.0001). BMD values of
the arms at baseline were significantly lower in the patents’
group (  0.034; P  0.0001); after 1 yr of follow-up, the
difference between the two groups was greater and still
significant (  0.052; P  0.0001). HIV patients showed
markedly lower BMD values of the legs compared with con-
trol subjects both at baseline ( 0.044; P  0.0001) and at
follow-up (  0.062; P  0.0001).
During the follow-up period, spinal BMD (sBMD) of HIV
patients increased on average by 0.069 (0.01) g/cm2. The
increment observed was not statistically different (t  1.3;
P  0.17) from the sBMD increase expected for healthy chil-
dren [0.055 (0.003) g/cm2]. Whole body BMD of HIV patients
increased by 0.016 (0.007) g/cm2 over 12 months. The ob-
served increment was significantly different (t  2.8; P 
0.0038) from that estimated for healthy children [0.035 (0.002)
g/cm2]. The annual BMD increment of the arms observed in
our patients was 0.014 (0.004) g/cm2, whereas the increment
estimated for healthy children was 0.032 (0.001) g/cm2. The
difference was highly significant (t  4.0; P  0.0004). The
BMD increment of the legs of HIV patients [0.050 (0.013)
g/cm2] did not differ from the estimated one [0.054 (0.002)
g/cm2; t  0.23; P  0.81].
Analyses comparing subjects grouped according to the
clinical stage of the disease and the degree of immunodeple-
tion did not show differences in BMD measurements.
Biochemical measurement
Serum BALP and urine NTx concentrations measured at
baseline and after 12 months are shown in Table 2. Mean
BALP levels of control children were 105.3 (6.0) U/liter,
whereas mean NTx concentration was 230.5 (11.6) nmol
BCE/mmol creatinine.
Multivariate models for BALP included sex, age, Tanner
stage, and anthropometric measurements as confounding
variables. BALP serum levels of HIV patients were signifi-
cantly higher compared with controls at baseline [  17.9
(5.2); P  0.0008]. After 1 more year of HAART, the BALP
serum levels were still higher than those of control subjects
[  20.6 (5.2); P  0.0002].
The multiple regression models for the analyses of NTx
were similar to the former, and included sex, age, weight,
and height as confounding variables. At baseline HIV pa-
tients had NTx values significantly higher than those of
healthy children [ 97.7 (13.6); P 0.0001]. The difference
between the two groups was reduced after 1 yr [  79.8
(15.0)], but still significant (P  0.0001).
The mean difference of BALP serum levels observed in
HIV patients was 2.8 (6.4) U/liter, significantly different (P
0.033) from that estimated for healthy children [11.1 (1.9)
U/liter]. The NTx urine measurements of HIV children
showed a net mean decrease [81.1 (45.3) nmol BCE/mmol
creatinine]. However, the observed value was not statisti-
cally different (P  0.27) from that estimated for control
subjects [26.6 (4.5) nmol BCE/mmol creatinine].
Discussion
Bone density and bone metabolism changes during
HAART treatment in HIV-infected children are largely un-
known. The present study was designed to monitor vertically
HIV-infected children in a short-term follow-up study. BMD
was measured at baseline and after 1 yr at lumbar spine and
whole skeleton by dual-energy x-ray absorptiometry. Bone
mass measurements obtained with dual-energy x-ray ab-
sorptiometry are largely influenced by the size of the bone
TABLE 2. Bone mineral measurements and bone metabolism
indexes of 32 vertically HIV-infected children at baseline and after
12 months of additional exposure to highly active antiretroviral
therapy
Baseline After 12 months
Lumbar spine BMD (g/cm2) 0.803 (0.034) 0.875 (0.034)
Total body BMD (g/cm2) 0.913 (0.020) 0.933 (0.022)
Arms BMD (g/cm2) 0.647 (0.016) 0.665 (0.016)
Legs BMD (g/cm2) 0.923 (0.035) 0.980 (0.036)
BALP (U/liter) 124.1 (9.0) 127.2 (9.1)
NTx (nmol BCE/mmol creatinine) 454.8 (49.9) 329.2 (36.1)
Data are expressed as mean (SE).
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(31). This is particularly important when changes occur over
time, as in children and adolescents who increase bone mass
and bone size. For this reason, several methods have been
proposed to overcome the problem (32). In the current study,
we used multivariate analyses to compare the bone mineral
measurements of HIV patients and control subjects and to
control for the confounding effect of sex, age, pubertal de-
velopment, and anthropometric measurements (33). After
correction of confounding variables, we found that BMD
values were markedly lower at both sites compared with
healthy children. This finding confirms previous reports that
showed significantly decreased values of bone density in
perinatally HIV-infected girls (12), in prepubertal children
(15), and in HAART-treated children and adolescents (13).
Longitudinal surveys performed in adult patients showed
a variable degree of improvement of bone mineral measure-
ments during HAART (24, 25). These data suggest that the
amount of BMD gained depends on CD4 cells increase and
HIV suppression, although the rate of increase of BMD might
be slow. The BMD values of our patients increased compared
with baseline after an additional year of HAART, but they
remained significantly lower than those of control subjects.
To better define the evolution over time of BMD in our
patients, we estimated from our control population the in-
creases of BMD that would occur in healthy children, and we
compared them with those observed in HIV patients. The
analyses showed that BMD measured at the lumbar spine
increased at a rate comparable to that estimated for healthy
children and adolescents. Conversely, whole skeleton BMD
increased at a much lower rate. Moreover, analyses of the
evolution of bone density of the limbs showed that BMD
increments of the legs were comparable to the ones estimated
for healthy children. On the contrary, BMD values of the
arms changed at a much lower rate than expected. Although
the design of the study does not allow us to determine exactly
the role of HAART in determining low bone mass, our data
indicate that HAART treatment in children does not lead to
a short time recovery of BMD, as seen in adult patients.
Moreover, these results suggest a differential effect of treat-
ment on bone mineral accretion. Weight-bearing sites (axial
skeleton, legs) grow at a normal rate, whereas non-weight
bearing sites show a slower growth rate. The reasons for this
observation are unclear. We speculate that the beneficial
effect of weight on bone mineral accretion might counteract
a deleterious effect of treatment on the skeleton. However,
longer follow-up studies are needed to confirm these
findings.
There is evidence for alterations of bone metabolism in
adult (6, 25, 34) and young (13, 14) HAART-treated HIV
patients. However, data from adult patients are discordant,
showing either low bone formation rate (6, 34) or elevated
serum levels of bone formation markers (25, 34). Similarly,
bone resorption was found to be enhanced (25, 34), or normal
(6). Findings for HIV youth are somehow different. Bone
formation indexes (osteocalcin, BALP, propeptide of type I
procollagen) have been found to be very elevated in HAART-
treated young patients (13, 14). Moreover, bone resorption
rate has been found to be higher than normal (13). In the
present study we found elevated measurements of BALP and
NTx at baseline and after an additional year of treatment.
Moreover, the data on the annual changes showed that both
indexes decrease at a lower (BALP) or similar (NTx) rate
compared with estimated values obtained from the control
population. These data confirm and extend previous obser-
vations and indicate that bone metabolism alterations do not
improve over time during HAART in HIV children and
adolescents. High bone metabolism rate could explain low
bone density values, because high bone turnover rate is as-
sociated with osteopenia and osteoporosis (35). Our data,
however, do not indicate whether high bone metabolism rate
is the consequence of HAART or whether it is the expression
of a direct effect of the HIV infection, because there is evi-
dence for a possible direct role of HIV on bone cells (11).
These results might also be the consequence of vitamin D
deficiency. However, no alterations of PTH or vitamin D
were found in our patients during HAART treatment (our
unpublished observation).
In summary, the present data indicate that bone metabo-
lism derangement is present in children on long-term
HAART. These alterations might be the cause of the observed
low BMD values. Moreover, there was only a partial im-
provement in bone mass measurements over time. Never-
theless, HIV-infected children and adolescents seem at great
risk of not obtaining an optimal bone mass. Therefore, im-
pairments in obtaining an optimal bone mass should be
prevented to avoid future complications, and the role of
possible therapeutic approach should be urgently assessed.
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